GlassScriptPhysician profile
Idelfia A Marte
NPI 1629023080
$18,178.74
in general payments reported to CMS, 2019-2025
56 companies · $1,884 in 2025
The $1,884 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,416 · 2020: $690 · 2021: $1,213 · 2022: $4,755 · 2023: $3,182 · 2024: $2,040 · 2025: $1,884.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,645 · Consulting Fee: $1,350 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,644.95 |
| Consulting Fee | $1,350.00 |
| Education | $110.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $3,950.59 | 2021-2025 | Datroway, Enhertu |
| Verastem, INC. | $2,669.77 | 2019 | |
| Janssen Biotech, INC. | $1,940.91 | 2019-2025 | Rybrevant |
| Novartis Pharmaceuticals Corporation | $1,007.81 | 2019-2025 | |
| Celgene Corporation | $813.55 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Pfizer INC. | $766.51 | 2019-2025 | |
| Gilead Sciences, INC. | $625.21 | 2021-2025 | Trodelvy |
| Genzyme Corporation | $486.65 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $480.24 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Merck Sharp & Dohme LLC | $406.23 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Seagen INC. | $391.53 | 2019-2023 | Adcetris, Tukysa |
| Astrazeneca Pharmaceuticals LP | $350.59 | 2020-2024 | Lynparza, Calquence |
| Pharmacyclics LLC, An Abbvie Company | $336.23 | 2021-2023 | Imbruvica |
| Glaxosmithkline, LLC. | $312.89 | 2020-2025 | Ojjaara, Blenrep, Jemperli |
| Array Biopharma INC | $280.72 | 2019-2025 | Braftovi, Mektovi, Lorbrena |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $244.02 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Genentech USA, INC. | $241.83 | 2019-2023 | Venclexta |
| Abbvie INC. | $221.31 | 2019-2025 | |
| Exelixis INC. | $203.76 | 2020-2025 | Cabometyx |
| Takeda Pharmaceuticals U.S.A., INC. | $191.85 | 2019-2023 | Alunbrig |
| Amgen INC. | $166.34 | 2019-2022 | |
| Taiho Oncology, INC. | $144.15 | 2020-2025 | |
| Beigene USA, INC. | $143.57 | 2022-2024 | Brukinsa |
| Rigel Pharmaceuticals, INC. | $141.42 | 2024-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Tesaro, INC. | $128.36 | 2019 | |
| Eisai INC. | $127.69 | 2021-2023 | |
| Genmab U.S., INC. | $125.00 | 2024 | Epkinly |
| Dova Pharmaceuticals | $125.00 | 2019 | |
| Incyte Corporation | $120.99 | 2020-2024 | Jakafi, Monjuvi |
| Epizyme, INC. | $108.47 | 2021 | |
| Sanofi-Aventis U.S. LLC | $99.99 | 2023 | |
| Progenics Pharmaceuticals, INC. | $98.00 | 2023 | Pylarify |
| Sobi, INC | $79.67 | 2025 | |
| Astellas Pharma US INC | $79.65 | 2019-2025 | Xtandi, Padcev |
| Kite Pharma, INC. | $76.32 | 2021-2023 | Yescarta |
| Jazz Pharmaceuticals INC. | $45.95 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.42 | 2019-2022 | |
| Puma Biotechnology, INC. | $35.09 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.03 | 2023 | |
| Myovant Sciences INC. | $34.72 | 2021-2022 | |
| Blueprint Medicines Corporation | $31.02 | 2021-2025 | Ayvakit |
| Beone Medicines USA, INC. | $27.96 | 2025 | Brukinsa |
| Dendreon Pharmaceuticals LLC | $27.64 | 2025 | Provenge |
| Regeneron Healthcare Solutions, INC. | $25.60 | 2023 | Libtayo |
| Alnylam Pharmaceuticals INC. | $23.11 | 2024 | Givlaari |
| Sumitomo Pharma America, INC. | $20.89 | 2025 | Orgovyx |
| Janssen Pharmaceuticals, INC | $17.39 | 2019 | |
| Hologic Sales and Service, LLC | $16.57 | 2023 | Novasure, Myosure Tissue Removal Device, Acessa Provu System |
| Pharmaessentia USA Corporation | $16.02 | 2024 | Besremi |
| Deciphera Pharmaceuticals INC. | $15.77 | 2022 | |
| Kyowa Kirin, INC. | $15.75 | 2024 | Poteligeo |
| Secura Bio, INC. | $15.35 | 2024 | Copiktra |
| Advanced Accelerator Applications | $15.19 | 2020 | |
| Cti Biopharma Corp. | $14.84 | 2022 | |
| Acrotech Biopharma INC. | $11.97 | 2022 | |
| Veracyte, INC. | $0.64 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Idelfia Marte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.